Telomir Pharmaceuticals (NASDAQ: TELO) has announced the publication of peer-reviewed preclinical data in Advances in Redox Research demonstrating that Telomir-Zn, its lead small-molecule therapeutic, delivers dose-dependent survival improvements and multiple therapeutic benefits in a Wilson's disease model. The study showed that Telomir-Zn reduced oxidative stress, lowered hepatic copper burden, and improved liver function markers, supporting the compound's biological activity in Wilson's disease.
Wilson's disease is a genetic disorder characterized by excessive copper accumulation in the body, particularly in the liver and brain, leading to severe organ damage if untreated. The preclinical findings expand the scientific validation of Telomir-Zn as the company advances its lead triple-negative breast cancer program toward Phase 1/2 clinical initiation. The results are significant because they demonstrate the compound's potential beyond oncology, targeting fundamental mechanisms of metal homeostasis and oxidative stress implicated in degenerative diseases.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics that target epigenetic and metabolic mechanisms in cancer, aging, and degenerative disease. The company's lead program, Telomir-1 (Telomir-Zn), has shown activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. The latest news and updates relating to TELO are available in the company's newsroom at https://ibn.fm/TELO.
The publication in a peer-reviewed journal adds credibility to the findings and underscores the potential of Telomir-Zn as a therapeutic agent for Wilson's disease, a condition with limited treatment options. The data support the biological activity of Telomir-Zn and pave the way for further development. For more details on the press release, visit https://ibn.fm/fOSNo.